The future of sexual medicine for the urologist is part of a larger issue of defining the specialty's scope and role in the 21st century and how urologists will meet patient needs. Sexual medicine is a discipline that bridges both the physiological and psychological realms. Sexual health and function may be altered by endocrinological or neurological disorders, cancer and its therapies, vascular disease, and a variety of psychological issues.
Urologists have concentrated on the physiology of ED and treatment has evolved into four generally accepted modalities: oral administration of PDE-5 inhibitors; vaso-active drug therapy; vacuum erection devices; and implantation of penile prostheses. The first line of therapy is almost always the use of oral drugs, with most patients preferring this to the intra-urethral or intra-cavernosal routes required for vaso-active therapy. Many patients cannot use PDE-5 inhibitors owing to cardiovascular disease and the need for nitrate-containing drugs and many find the other more invasive therapies unacceptable. There has been less interest in female sexual dysfunction although attempts to study PDE-5 inhibitors in women and the role of testosterone in female sexual function have been considered. Recently, the federal government, through Medicare has taken the position that sexual dysfunction is not a disease, but a 'lifestyle' issue and is considering reversing its decision to cover PDE-5 inhibitors for its beneficiaries. Given these issues what should the role of the urologist be in the future of sexual medicine?
Recent data from the American Board of Urology, obtained from surgical logs of urologists seeking re-certification, suggests that practice patterns are not closely related to residency training program goals. Most practicing urologists perform relatively few of the major index cases that define residency training program requirements and are expanding their office practices while their surgical practices are weighted to endoscopic procedures. The American Urological Association is spearheading a task force to study the nature of urological training and to consider what the urologist of the 21st century should be. I view this as the ideal time to expand the role of the urologist in the field of sexual medicine. We initially entered the field as surgeons, developing and utilizing implantable penile prostheses. As more research led to understanding the neuro-muscular and vascular physiology of the penile cavernous tissue, we applied vaso-active drug therapy to replace surgical interventions and quickly adopted oral medical therapy when PDE-5 inhibitors were discovered.
We must now move forward to include training future urologists in all aspects of sexual dysfunction and its treatment including surgical, medical and psychological. As we have a long tradition as male and female pelvic surgeons and understand the physiology of voiding dysfunction and pelvic anatomy, we should be in the forefront of managing sexual disorders in the male and the female. This will require investment in basic research in sexual physiology and collaboration with our gynecological and psychiatry colleagues. As we continue to press for coverage from Medicare and third-party payers for benign and malignant diseases of the prostate, bladder and kidney, we must also educate patients, legislators, and insurance executives, so that sexual dysfunction is understood as a disease that can significantly affect the health of those afflicted. Although we think of ourselves as genitourinary surgeons, we have always embraced non-surgical treatments for genitourinary diseases. Just as we moved from open stone surgery to ureteroscopy and ESWL, from maximally invasive surgical procedures to laparoscopic, and now, robot-assisted surgery, so too must we encompass all therapies for sexual dysfunction and lead the development of new knowledge and treatments in this field.
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